Table 1 Baseline and clinical characteristics of 118 severe COPD patients attended for COPD exacerbation (ECOPD), with and without P. aeruginosa isolation
Whole group | PA-group | Non PA-group | P value | |
|---|---|---|---|---|
Subjects, (%) | 118 | 41 (34.7) | 77 (65,3) | … |
Follow-up (days), m (SD) | 1003±306 | 1036.9±347.5 | 984.9±282.3 | 0.41 |
Age (years), m (SD) | 69.5±8.2 | 70.3±7.7 | 69±8.5 | 0.42 |
Current smoking, (%) | 13 (11) | 2 (4.9) | 11 (14.3) | 0.21 |
Pack-year, m (SD) | 63.3±31,9 | 69.4±36.3 | 60±28.9 | 0.15 |
Alcohol abuse >80 g/l, n (%) | 3 (2.5) | 1 (2.4) | 2 (2.6) | 1 |
Influenza vaccination, n (%) | 105 (89) | 38 (92.7) | 67 (87) | 0.53 |
Pneumococcus vaccination n (%) | 57 (48.3) | 23 (56.1) | 34 (44.2) | 0.21 |
Body mass index (Kgr/m 2 ) | 27.5±4.6 | 26.5±4 | 28.1±4.9 | 0.17 |
FEV1 post-BD, (L), m (SD) | 0.97±0.3 | 0.91±0.28 | 1.0±0.31 | 0.13 |
FEV1 post-BD, (% predicted), m (SD) | 34±11 | 34±13 | 34.3±10 | 0.82 |
GOLD stage IV, n (%) | 71 (60) | 27 (66) | 44 (57) | 0.35 |
BODE score, m (SD) | 5.1±1,6 | 5.3±1,5 | 5±1.6 | 0.38 |
Home oxygen therapy, n (%) | 50 (42.4) | 21 (51.2) | 29 (37.7) | 0.15 |
Charlson, m (SD) | 4.13±1.5 | 4.29±1.5 | 4.04±1.5 | 0.39 |
Bronchiectasis score, m (SD) | 2.1±2,6 | 3±3.5 | 1.6±1.8 | 0.02 |
ECOPD during follow-up, m (SD) | 3.19±2.9 | 4.4±4 | 2.5±2 | 0.008 |
ECOPD/year, m (SD) | 2.19±2 | 3±2.7 | 1.7±1.4 | 0.006 |
Antibiotic prescriptions* | 8.9±7.5 | 12.5±9.2 | 7.01±5.7 | <0.001 |
Antibiotic prescriptions/year | 3.3±2.5 | 4.7±2.9 | 2.6±1.8 | <0.001 |
Corticosteroid courses* | 6.3±5.8 | 8±6.3 | 5.5±5.4 | 0.02 |
Corticosteroid courses/year | 2.30±1.8 | 2.9±2 | 1.9±1.6 | 0.004 |
Days of hospital stay* | 29.4±37.9 | 43.8±43.9 | 21.3±31.9 | 0.005 |
Mortality, n (%) | 17 (14.4) | 11 (27) | 6 (8) | 0.005 |